Proqr Therapeuti - PRQR STOCK NEWS

ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the RNA Editing Summit from June 18-20, 2024, in Boston. Gerard Platenburg, Chief Scientific Officer and Co-Founder, will present on June 20 at 2:00pm ET. The presentation, titled “Developing Axiomer RNA Editing Technology Towards Clinical Development,” will focus on ProQR’s ADAR-mediated Axiomer RNA editing technology, optimization strategies, and the AX-0810 program targeting NTCP for cholestatic diseases. The presentation will also cover in vivo models of biomarkers for NTCP and will be accessible on ProQR’s website under Presentations & Publications.

ProQR Therapeutics NV. (Nasdaq: PRQR) reported Q1 2024 financial results, highlighting preclinical data for the AX-0810 program targeting NTCP for cholestatic diseases. The company presented successful defense of its IP estate and announced Martin Maier, PhD's nomination to the Board. ProQR emphasized its strong cash position of €102.7 million providing runway into mid-2026.

ProQR Therapeutics NV announced preclinical proof of concept data for its AX-0810 Axiomer™ RNA editing program targeting NTCP for cholestatic diseases. The data, presented at the ASGCT Annual Meeting, revealed significant progress in RNA editing technology. The AX-0810 program aims to reduce bile acid concentration in the liver by targeting NTCP, representing a promising approach for cholestatic disorders. The company plans to advance the program to the clinic in late 2024/early 2025, with additional milestones expected for the Axiomer pipeline.

ProQR Therapeutics NV. (Nasdaq: PRQR) announced the nomination of Martin Maier, PhD, to its Board of Directors and the upcoming Annual General Meeting of Shareholders on May 22, 2024. Dr. Maier, with extensive experience in RNA platforms and therapeutics, will bring valuable insights to the company. The AGM will also see a change in the Board structure to a one-tier system, with Dinko Valerio stepping down as chairperson. James Shannon, MD, will assume the role of chairperson.

ProQR Therapeutics NV (Nasdaq: PRQR) announced new preclinical data for its Axiomer™ RNA editing technology platform at the ASGCT Annual Meeting. The company introduced the first preclinical data for its AX-0810 pipeline program targeting NTCP for cholestatic diseases. ProQR highlighted the robust editing efficiency of Axiomer editing oligonucleotides and the potential for cholestatic disease treatment.

ProQR Therapeutics N.V. successfully defended its key patent for the Axiomer™ RNA editing platform against opposition filed in June 2021, maintaining its strong IP position. The European Patent Office ruled in favor of ProQR, protecting its chemically modified editing oligonucleotides that recruit endogenous ADAR for RNA editing. ProQR's extensive patent portfolio includes 28 patents and 15 published patent families, solidifying its leading position in ADAR-mediated RNA editing technology.

ProQR Therapeutics NV (PRQR) reported financial results for 2023, highlighting progress in RNA editing technology. The company strengthened its IP estate, formed partnerships, and divested ophthalmic assets. ProQR anticipates sharing pipeline program data in 2024 and entering the clinic by late 2024/early 2025. The company holds €118.9 million in cash, providing runway into mid-2026.

ProQR Therapeutics N.V. announced the successful defense of its patent in Japan for its ADAR-mediated RNA editing platform Axiomer™. The Japanese Patent Office rejected the opposition, maintaining all claims as granted to ProQR. The company's strong IP position in RNA editing using oligonucleotides and endogenous ADAR is further reinforced by this decision.

ProQR Therapeutics NV highlights robust in vivo editing capabilities of its Axiomer RNA editing technology platform, demonstrating up to 70% editing of ACTB in the liver of non-human primates and mice. Functional effect demonstrated in mice via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkers. Additional data to be presented in 2024 for pipeline programs targeting Cholestatic diseases and Cardiovascular diseases.